Home Stocks DRMA Dermata Therapeutics Inc (NASDAQ: DRMA) Healthcare · Biotechnology
— —
Quote unavailable · Price data is temporarily unavailable.
The Quantellect read. Short interest is 2.56% of float with a 182.54% borrow fee. Descriptive summary of the data on this page, not a recommendation.
Momentum Neutral RSI (14) 35.5 (overbought above 70, oversold below 30)
Short interest 2.6% of float FINRA settlement Oct 30, 2026
DRMA price chart Price — · As of —
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open —
Previous close —
Day range —
52-week range $0.54 – $3.14 Through Nov 18, 2026
Volume —
Average volume (30 calendar days, 0 sessions) — Through Nov 18, 2026
Market cap $3.06M
P/E (TTM) 0.1
Forward P/E —
EPS (TTM) −$4.39
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) 0.63
Price history DRMA · NASDAQ · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
Industry comparison — · Industry comparison not available
Upcoming events — · Upcoming events not available
Analyst consensus — · Analyst consensus not available
Earnings history EPS, last 8 quarters −10.00 −8.00 −6.00 −4.00 −2.00 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$0.55 −$0.55 —
Q2 2026 −$0.55 −$0.74 —
Q1 2026 — −$0.48 —
Annual 2025 −$1.54 −$8.16 —
Q3 2025 — −$1.65 —
Q2 2025 — −$1.66 —
Q1 2025 −$0.45 −$0.45 —
Annual 2024 −$0.32 −$8.03 —
Smart-money activity In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
Date Type Who Action Amount Source
Jun 16, 2026 Insider sell Scott Kathleen D. Sell $13 Form 4 Feb 17, 2026 Insider buy Bedoya-Toro Munera Maria E Buy $1.3K Form 4 Nov 23, 2021 Insider buy PROEHL GERALD T Buy $48K Form 4 Aug 17, 2021 Insider buy HALE DAVID F Buy Unavailable Form 4 All smart-money activity →
News and press releases Year All 2026 2025 Oct 29, 2026, 4:05 PM ET May 13, 2026, 3:00 AM ET Mar 26, 2026, 3:00 AM ET All DRMA news → Company profile Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
CEO Mr. Gerald T. Proehl
Headquarters San Diego, CA, United States
Employees 9
IPO date Aug 13, 2021
Sector Healthcare
Industry Biotechnology Q Score — · Q Score not available
Upcoming events — · Upcoming events not available
Analyst consensus — · Analyst consensus not available
Earnings history EPS, last 8 quarters −10.00 −8.00 −6.00 −4.00 −2.00 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$0.55 −$0.55 —
Q2 2026 −$0.55 −$0.74 —
Q1 2026 — −$0.48 —
Annual 2025 −$1.54 −$8.16 —
Q3 2025 — −$1.65 —
Q2 2025 — −$1.66 —
Q1 2025 −$0.45 −$0.45 —
Annual 2024 −$0.32 −$8.03 —
Company profile Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
CEO Mr. Gerald T. Proehl
Headquarters San Diego, CA, United States
Employees 9
IPO date Aug 13, 2021
Sector Healthcare
Industry Biotechnology